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Abstract
The pathogenesis of type 2 diabetes mellitus (T2DM) is closely associated with mitochondrial functions in insulin-
responsive tissues. The mitochondrial proteome, compared with the mitochondrial genome, which only contains 37
genes in humans, can provide more comprehensive information for thousands of mitochondrial proteins regarding
T2DM-associated mitochondrial functions. However, T2DM-associated protein signatures in insulin-responsive tissues
are still unclear. Here, we performed extensive proteome proﬁling of mitochondria from skeletal muscles in nine T2DM
patients and nine nondiabetic controls. A comparison of the mitochondrial proteomes identiﬁed 335 differentially
expressed proteins (DEPs) between T2DM and nondiabetic samples. Functional and network analyses of the DEPs
showed that mitochondrial metabolic processes were downregulated and mitochondria-associated ER membrane
(MAM) processes were upregulated. Of the DEPs, we selected two (NDUFS3 and COX2) for downregulated oxidative
phosphorylation and three (CALR, SORT, and RAB1A) for upregulated calcium and protein transport as representative
mitochondrial and MAM processes, respectively, and then conﬁrmed their differential expression in independent
mouse and human samples. Therefore, we propose that these ﬁve proteins be used as a potential protein proﬁle that
is indicative of the dysregulation of mitochondrial functions in T2DM, representing downregulated oxidative
phosphorylation and upregulated MAM functions.
Introduction
A growing volume of evidence has shown that mito-
chondrial functions can play important roles in the
pathogenesis of type 2 diabetes mellitus (T2DM). Mito-
chondria are intracellular organelles that are responsible
for ATP production from glucose and fatty acid oxidation.
Thus, they are essential for various cellular events that
require ATP, such as cell proliferation or differentiation.
T2DM is characterized by both impaired insulin secretion
and insulin resistance. Mitochondrial dysfunction in
pancreatic beta cells impairs glucose-induced insulin
secretion1. Moreover, mitochondrial dysfunction in ske-
letal muscles is also associated with decreased fatty acid
oxidation, the accumulation of intracellular lipid meta-
bolites, and inhibition of the insulin signaling pathway2.
These data suggest close associations of mitochondrial
functions with the pathophysiology of T2DM in both
insulin-secreting and responsive tissues.
In many diseases, genomic or proteomic proﬁles pro-
vide molecular signatures to deﬁne the states related to
the diseases. The human mitochondrial genome (mtDNA)
has provided a molecular basis for understanding various
diseases, such as neurodegenerative diseases, cancers, and
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T2DM3–5. Over 150 mtDNA mutations have been asso-
ciated with such diseases, as well as other maternally
inherited syndromes6. Nonetheless, considering that the
mtDNA includes 37 genes and encodes only 13 proteins,
the capacity for mtDNA mutations to account for the
pathophysiology of these diseases is limited. By contrast,
proteomic proﬁles also provide unique, complementary
information that links genotypes to phenotypes. Thou-
sands of both nucleus-encoded and mitochondria-
encoded proteins are localized in mitochondria, deﬁning
mitochondrial functions associated with the diseases.
Thus, compared with mitochondrial genome, the mito-
chondrial proteome can provide more comprehensive
information for thousands of mitochondrial proteins,
which can be used to evaluate mitochondrial functions
associated with T2DM.
Recent advances in mass spectrometry (MS)-based
proteomic methods have improved the size of detected
mitochondrial proteomes to more than 1500 mitochon-
drial proteins7. The large proteome size suggests that not
only metabolic pathways but also other cellular pathways,
such as those for calcium homeostasis, apoptosis,
and signal transduction, are active in mitochondria. Thus,
comprehensive mitochondrial proteomes in insulin-
responsive tissues can provide a molecular basis for
understanding T2DM-associated mitochondrial dysregu-
lation of such metabolic and cellular pathways. To search
for proteome proﬁles associated with the pathogenesis of
T2DM, several studies have described the global pro-
teome proﬁles of tissue and serum samples from T2DM
patients or mouse models8–12. For example, Li et al.8 have
identiﬁed 68 proteins that are upregulated in the sera
of T2DM patients, found a signiﬁcant association of the
complement system with T2DM, and then selected ﬁco-
lin-3, an upstream activator of the complement cascade,
as a protein that is indicative of T2DM-associated com-
plement activation. However, to our knowledge, no
comparative study of mitochondrial proteomes in insulin-
responsive tissues from T2DM patients and nondiabetic
controls has been performed to identify the proteome
proﬁles indicative of mitochondrial functions in T2DM.
Here we performed extensive proteome proﬁling of
mitochondria isolated from skeletal muscles in T2DM
patients (n= 9) and nondiabetic controls (n= 9) to
understand the mitochondrial proteome proﬁles asso-
ciated with T2DM. For protein digestion, we employed
ﬁlter-aided sample preparation (FASP)13 to improve
detection of the proteins incorporated in both inner and
outer mitochondrial membranes. Furthermore, the use of
ultra-high pressure nano-LC-MS/MS coupled with
extensive fractionation provided comprehensive mito-
chondrial proteomes, including 23,122 peptides for 1150
proteins, thereby enabling a thorough comparative ana-
lysis of mitochondrial proteomes between skeletal
muscles from T2DM patients and nondiabetic controls.
From the measured mitochondrial proteomes, we selected
hundreds of differentially expressed proteins (DEPs) in
skeletal muscles from T2DM patients. Through func-
tional and network analyses, among the DEPs, we selected
a protein proﬁle indicative of mitochondrial functions in
diabetic skeletal muscles.
Materials and methods
Sample collection
We collected two independent sets of skeletal muscles
from T2DM and control subjects who underwent elective
orthopedic surgery in Seoul National University Bundang
Hospital. The ﬁrst set of nine T2DM patients and nine
nondiabetic control subjects were used for proﬁling
mitochondrial proteomes. We enrolled T2DM patients
who were diagnosed with diabetes based on American
Diabetes Association (ADA) criteria14. The control group
was enrolled based on the same ADA criteria. To conﬁrm
the validity of the selected mitochondrial proteins
indicative of T2DM by western blotting, we collected
the second set, which included 14 T2DM patients and
12 nondiabetic control subjects. Informed consent was
obtained from all subjects. This study was conducted
according to the Declaration of Helsinki and was
approved by the ethics committees of SNUH [SNUBH
IRB# B-0710/050-009]. The clinical characteristics of all
enrolled patients for proteome proﬁling and for con-
ﬁrming candidate proteins are described in Supplemen-
tary Table 1.
Animal experiments
C57BL/6 mice (Orient Bio, Seongnam, Gyeonggi-do,
Korea) were fed a normal chow diet [Purina LabDiet,
Purina Mills (St Louis, MO)] and a HFD [60% high fat and
high sucrose, Research diet (New Brunswick, NJ)] for
12 weeks at 6 weeks after birth. All animal studies were
approved by the Institutional Animal Care and Use
Committee of Seoul National University Hospital (Permit
Number: SNU-150126-1-3).
Isolation of mitochondria
We isolated mitochondria from wild-type cybrid cells15
and skeletal muscle tissues as previously described16. The
cells and tissues were homogenized in mitochondria
isolation buffer (250 mM sucrose and 1 mM EDTA in
25mM Tris-HCl pH 7.4) at 4 °C. Subsequently, the lysates
were centrifuged at 1000 × g to the separate nuclear and
cytosolic fraction, and the cytosolic fraction was further
centrifuged at 10,000 × g at 4 °C to obtain a crude mito-
chondrial pellet. The isolated mitochondria were further
puriﬁed through a 10–40% Percoll gradient by cen-
trifugation at 20,000 rpm in a Beckman SW41 rotor for
120min. The upper and lower fractions (P1 and P3
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fractions, respectively) of the mitochondrial layer in the
gradient were carefully discarded. The remaining mito-
chondrial layer (P2 fraction) was washed twice and stored
at –70 °C until use.
Mitochondrial protein and peptide preparation
Isolated mitochondria from skeletal muscle tissues and
cybrid cells were dissolved in 4% SDS lysis buffer in
Tris HCl at pH 7.6, and the solution was transferred into
1.5-ml e-tubes containing 2-mm glass beads. The mito-
chondria were disrupted by repeated strokes at 1000 rpm
for 30 s using a Mini-BeadBeaterTM Mill (Cole-Parmer
Instrument, Vernon Hills, IL) and cooled on ice for
1 min17. This procedure was repeated until no pellets
were visible (~10–15 times). The supernatants were
transferred to a new tube and centrifuged at 5000 rpm for
10min at 20 °C to remove the debris. The resulting
supernatant was transferred to a new tube, sonicated
using a Q55 Sonicator (Qsonica, Newtown, CT) for 30 s,
and subjected to cooling for 1 min. The sonicated lysis
procedure was repeated 10 times on ice. The lysate was
centrifuged at 14,000 × g for 10 min at 20 °C, the super-
natant was transferred to a new tube, and the protein
concentration was determined using a BCA protein assay
(Pierce, Rockford, IL) and bovine serum albumin.
Mitochondrial peptide samples were prepared using a
modiﬁed FASP method13. Brieﬂy, 100 μg of protein lysate
was reduced in 100 μL of SDT (4% SDS and 0.1M DTT in
0.1M Tris-HCl, pH 7.6) solution for 45 min at 37 °C and
then boiled for 10 min to increase the denaturation. After
sonication for 10min, the sample was centrifuged for
5 min at 16,000 × g. The reduced protein sample was
mixed with 200 μL of 8M urea in a Microcon ﬁlter YM-30
(Millipore Corporation, Bedford, MA), and the ﬁlter was
centrifuged at 14,000 × g for 60 min. All centrifugation
steps were performed at 20 °C. To remove residual SDS,
200 μL of 8M urea in 0.1M Tris-HCl (pH 8.5) was added
to the ﬁlter before the ﬁlter was centrifuged at 14,000×g.
This washing step was repeated twice. Subsequently,
100 μL of 50mM iodoacetamide in 8M urea in 0.1M
Tris-HCl was added to the concentrate for alkylation at
25 °C for 25min in the dark, followed by centrifugation at
14,000 × g for 30min to remove the alkylation reagent.
The resulting sample was washed twice with 200 μL of
8M urea in 0.1M Tris-HCl and then twice with 100 μL of
50mM NH4HCO3. The alkylated protein sample was
subjected to proteolytic digestion using trypsin (1:50
enzyme-to-protein ratio (w/w), Promega, Madison, WI)
at 600 rpm for 1 min at 37 °C, followed by an overnight
incubation for 12 h with no shaking in a thermo-mixer
comfort (Eppendorf, Hamburg, Germany). The second
trypsin digestion (1:100 enzyme-to-protein ratio) was
carried out for 6 h. The digested peptides were eluted by
centrifugation at 14,000 × g for 20 min. The ﬁlter was
additionally rinsed with 60 μL of 50mM NH4HCO3 and
centrifuged at 14,000 × g for 30 min. The eluent was
mixed with the ﬁrst eluent. The peptide sample was dried
in a vacuum concentrator SPD1010 (Thermo, San Jose,
CA) and stored at −80 °C.
Fractionation of mitochondrial peptides by offgel
electrophoresis
The 500 μg of tryptic peptides from the P2 mitochon-
drial fraction of the cybrid cell was fractionated using a
3100 OFFGEL Fractionator (Agilent Technologies, Santa
Clara, CA) according to the manufacturer’s protocol. A
24-well tray was used with a 24-cm IPG gel strip of a
linear pH gradient ranging from 3 to 10 (Immobiline
DryStrip, GE Healthcare Life Sciences, Uppsala, Sweden),
and the gel strip was rehydrated for 15min with 25 μL of
the rehydration solution per well. The tryptic peptide was
dissolved in 0.72 mL deionized water and mixed with 2.88
mL of the offgel stock solution. In each well, 150 μL of the
resultant solution was placed. Focusing was performed at
20 °C with a voltage range from 500 to 8000 V and max-
imum current of 50 μA for 50 kVh. After focusing, the
peptide fractions from the 24 wells, as well as extra acid
(anodic ends) and extra base (cathodic ends) fractions,
were collected. To remove glycerol, spin desalting col-
umns were used. The peptides were then dried using
the vacuum concentrator.
LC-MS/MS experiments
Mitochondrial peptides were separated using a modiﬁed
version of the nanoACQUITY UPLC (NanoA, Waters,
Milford, MA) system18. An analytical column (75 μm
ID × 360 μm OD × 70 cm length) was manufactured in-
house by packing a fused-silica capillary (Polymicro
Technologies, Phoenix, AZ) with C18 materials (3 μm
diameter, 300 Å pore size, Jupiter, Phenomenex, Tor-
rance, CA) using acetonitrile slurry. The solid phase
extraction (SPE) column was prepared by packing the
same C18 materials into the 1-cm-long liner column
(250 μm ID) of an internal reducer (1/16” to 1/32”, VICI,
Houston, TX). The column temperature was set to 50 °C
using a semi-rigid gasline heater (1/4” ID, 60 cm long,
WATLOW, Winona, MN)19. The LC separation gradient
was 98% solvent A (0.1% formic acid in H2O) for 5 min,
2 to 50% solvent B (0.1% formic acid in 99.9% acetonitrile)
for 115min, 50 to 80% solvent B in 10min, and 80%
solvent B for 10 min. The ﬂow rate of the mobile phase
was set to 400 nL/min. A 7-tesla Fourier transform ion
cyclotron resonance mass spectrometer (FTICR, LTQ-FT,
Thermo Electron, San Jose, CA) was used to collect
the mass spectra. The eluted peptides from the LC were
ionized at an electrospray potential of 2.0 kV. The elec-
trospray ionization (ESI) emitter was made by chemical
etching of a fused-silica capillary emitter (20 μm ID × 150
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μm OD)20. The temperature of the desolvation capillary
was set to 250 °C. MS precursor ion scans (m/z 500–2000)
were acquired in full-proﬁle mode with an AGC target
value of 1 × 106, a mass resolution of 1 × 105, and a
maximum ion accumulation time of 500 ms. The mass
spectrometer was operated in a data-dependent tandem
MS mode, and the seven most abundant ions detected in a
precursor MS scan were dynamically selected for MS/MS
experiments incorporating a dynamic exclusion option
(exclusion mass width low= 1.10 Th; exclusion mass
width high= 2.10 Th; exclusion list size= 120; and
exclusion duration= 30 s) to prevent reacquisition of
MS/MS spectra of the same peptides. Collision-induced
dissociations of the precursor ions were performed in an
ion trap (LTQ) with the collisional energy and isolation
width set to 35% and 3 Th, respectively. The Xcalibur
software package (v. 2.0 SR2, Thermo Electron) was used
to construct the experimental methods. All LC-MS/MS
data were deposited in the ProteomeXchange Consortium
via the PRIDE21 partner repository with the dataset
identiﬁer PXD004312 and 10.6019/PXD004312 (User-
name: reviewer16736@ebi.ac.uk, Password: F64K10U7).
Peptide identiﬁcation
For peptide identiﬁcation, the integrated post experi-
ment monoisotopic mass reﬁnement (iPE-MMR) method
was ﬁrst used to process the LC-MS/MS data, as pre-
viously described22, before the subsequent protein data-
base search (Supplementary Figure S1a). Brieﬂy,
DeconMSn23 was used to generate MS/MS data (1st DTA
ﬁles), and precursor masses in the DTA ﬁles were
further corrected and reﬁned through PE -MMR24. The
mass-reﬁned DTA ﬁles (2nd DTA ﬁles) were subjected to
multivariate mass error correction using DtaReﬁnery25,26.
The DTA ﬁles were then converted to mgf ﬁles using
an in-house software, which was used for the MS-GF+
(ver. 9881)27 search against a composite target-decoy
database that contains forward and reverse protein
sequences of the uniprot human reference database
(April, 2014; 88,608 entries) and 179 common con-
taminants. A MS-GF+ search was performed with the
following parameters: precursor mass tolerance of
10 ppm, semi-tryptic, static modiﬁcation of carbamido-
methylation (57.021460 Da) to cysteine, and variable
modiﬁcations of oxidation (15.994920 Da) to methionine
and carbamylation (43.005810 Da) to N-termini. The
peptide spectrum matches (PSMs) were obtained using
the false discovery rate (FDR) of 1%.
Construction of a master accurate mass and time tag
(AMT) database (DB)
We next constructed a master AMT DB for the mito-
chondrial proteome using the identiﬁed peptides as
described previously (Supplementary Figure S1b)28.
Brieﬂy, the MS features of a peptide that emerged over a
period of LC elution time in a LC-MS/MS experiment
were ﬁrst grouped into a unique mass class (UMC) by PE-
MMR analysis (Supplementary Figure S1a)24. Ideally, a
peptide is represented by a UMC. The MS features of each
UMC included all of the mass spectral features of a
peptide, such as the charge state, abundance (intensity),
scan number, and measured monoisotopic mass. Pre-
cursor masses of MS/MS spectra were matched with
UMC masses and replaced with the matched UMC
masses (2nd DTA ﬁles, Supplementary Figure S1a). In this
process, DTA information was linked to the matched
UMC. After MS-GF+ search and target-decoy analysis,
the DTA ﬁle linked to the UMC resulted in a peptide
sequence (FDR ≤ 1%), and the peptide ID was recorded in
the UMC, called identiﬁed UMCs (UMC assignment,
Supplementary Figure S1b). Next, normalized elution
times (NETs) were calculated and calibrated for the
identiﬁed UMCs, as previously described29, and the cali-
brated NETs were recorded in the UMCs (NET calibrated
UMCs, Supplementary Figure S1b). The information for
these NET calibrated UMCs from all 80 LC-MS/MS
datasets (triplicate LC-MS/MS experiments of 18 samples
and 26 LC-MS/MS experiments of offgel fractionations)
was compiled into the master AMT DB (Oracle Database
10 g Enterprise Edition Release 10.2.0.1.0; Fig. 1a). When a
peptide was measured multiple times, the average mass
and median NET were recorded for the AMT for the
peptide (Supplementary Figure S1b).
Peptide assignment to unidentiﬁed UMCs using the AMT
DB
Due to the undersampling of the current proteomic
analysis platform, a large portion of UMCs from an LC-
MS/MS experiment was not identiﬁed by MS/MS
experiments and by protein database searches. For
example, for an LC-MS/MS dataset, 54,077 UMCs were
found, and only 5602 of them (ca. 10.4%) were identiﬁed
by protein database search (identiﬁed UMCs; Fig. 1b, right
top). Peptide IDs were assigned to these unidentiﬁed
UMCs using the AMT DB. Each unidentiﬁed UMC was
matched to the identiﬁed UMCs in the AMT DB using
the mass and NET tolerances (±10 ppm and ±0.025 NET),
and the peptide ID of the matched UMC in the AMT DB
was assigned to the unidentiﬁed UMC (Fig. 1b, right
bottom; Assigned UMCs, Supplementary Figure S1c).
This process resulted in 3363 additional UMCs identiﬁed
by the master AMT DB information, thereby increasing
the total number of UMCs with peptide ID assignments to
8965 (assigned UMCs).
Alignment of the identiﬁed peptides across samples
An MS intensity-based label-free quantitation method
was applied to an LC-MS/MS dataset as previously
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described28. Brieﬂy, for each assigned UMC, the intensity
(UMC intensity) was calculated during PE-MMR analysis
as the summation of abundances for all mass spectral
components of the UMC to represent the abundance of
the corresponding peptide24. The assigned UMCs from
the 54 LC-MS/MS datasets (i.e., triplicate LC-MS/MS
datasets of 18 individual mitochondria peptide samples)
were then combined into an alignment table in which
each row contains the peptide IDs with their corre-
sponding UMC intensities from each LC-MS/MS
experiment (UMC alignment, Supplementary Figure S1c).
Quantile normalization of the aligned data was performed
to correct systematic variations in peptide abundances
across individual LC-MS/MS datasets as previously
described30.
Analysis of mitochondrial proteomes
To identify DEPs between T2DM patients and non-
diabetic controls, we ﬁrst selected a set of peptides
(1) with corresponding proteins having more than two
non-redundant peptides and (2) with abundances that
were detected in more than 50% of all subjects in each
group to ensure their statistical power. For these selected
peptides, we then performed a statistical hypothesis
test that integrates Student’s t-test and log2-median
ratio test, as previously described15. Brieﬂy, for the
selected peptides, we (1) applied Student’s t-test and
log2-median ratio test to compute T-values and log2-
median ratios, (2) calculated the adjusted P-values of the
T-value and log2-median ratio for each peptide using
empirical null distributions for the two tests estimated
from random permutation experiments as previously
described31, (3) combined the adjusted P-values from
the two tests using Stouffer’s method32 for each peptide,
(4) selected differentially expressed peptides with
FDR ≤ 0.1 and ratio ≥ 1.5 after computing FDRs for the
combined P-values using Storey’s method33, and then
identiﬁed DEPs containing the differentially expressed
peptides. Moreover, to understand the cellular processes
associated with DEPs, functional enrichment analysis was
performed using DAVID software to identify GO biolo-
gical processes (GOBPs) represented by the DEPs34.
The GOBPs enriched by the DEPs were identiﬁed as those
with a P ≤ 0.05.
a
Mass Tolerance: ± 10ppm
RT Tolerance: ± 0.025 NET
M
ol
ec
ul
ar
 W
ei
gh
t (
D
a)
1000
0
0
2000
3000
4000
5000
6000
0.2 0.4 0.6 0.8 1.0
Normalized elution time (NET)
AMT DB
(42,132 AMTs)
1000
0
2000
3000
4000
5000
6000
0.2 0.4 0.6 0.8 1.0
Normalized elution time (NET)
An individual LC-MS/MS dataset
(5,602 Identified UMC)
0
Assigned UMC (8,965)
M
ol
ec
ul
ar
 W
ei
gh
t (
D
a)
 
M
ol
ec
ul
ar
 W
ei
gh
t (
D
a)
 
1000
0
2000
3000
4000
5000
6000
0.2 0.4 0.6 0.8 1.0
Normalized elution time (NET)
0
identified UMCs
additional identification using AMT DB
Skeletal muscle
NGT
(n = 9)
T2DM
(n = 9)
Mitochondria
Individual samples
(no fractionation)
LC-MS/MS analysis
(18x3)
Cybrid cells
Mitochondria
offgel
fractionation
LC-MS/MS analysis
(26)
Peptide identification Peptide identification
Identified UMCs Identified UMCs
AMT DB
(42,132 peptides 
or AMTs)
Assigned UMCs
Alignment &
quantification
Mitochondrial
proteome
b
c
Fig. 1 Master AMT DB of the mitochondrial proteome. a The overall scheme of AMT DB construction. A total of 80 datasets (18 × 3+ 24) were
generated from LC-MS/MS analysis. Each dataset was processed by iPE-MMR, after which a target-decoy MS-GF+ search was performed (peptide
identiﬁcation). The resultant peptides (or identiﬁed UMCs) were used to construct the AMT DB. b, c Utilization of the AMT DB to assign peptide IDs to
unidentiﬁed UMCs. The 42,132 AMTs (magenta dots) in the AMT DB are visualized in a 2D (NET and molecular weight) scatter plot (left). For a LC-MS/
MS dataset, the identiﬁed UMCs (blue dots) are shown in the upper right scatter plot. By matching the unidentiﬁed UMCs in this dataset with AMTs
using the indicated mass and NET tolerances, a subset of unidentiﬁed UMCs was assigned to peptide IDs of matching AMTs. These matched UMCs
(red dots) are shown in the bottom right scatter plot
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Reconstruction of the network model
To reconstruct a network model for DEPs, we ﬁrst
selected a subset of DEPs annotated with T2DM-related
GOBPs enriched by the DEPs and then collected their
protein–protein interactions for the selected DEPs
from four protein–protein interactome databases: BIND
(Biomolecular Interaction Network Database)35, HPRD
(Human Protein Reference Database)36, BioGRID (Biolo-
gical General Repository for Interaction Datasets)37, and
MINT (Molecular INTeraction Database)38. The initial
network model was built with the selected DEPs and their
interactors using Cytoscape39. We then arranged the
nodes according to their associated GOBPs and pathways
such that the nodes with similar functions were located
closely. The groups of nodes involved in the same GOBPs
were labeled with the corresponding GOBP.
Western blot analysis
For this analysis, we prepared total lysate and crude
mitochondrial samples from mouse skeletal muscle tis-
sues and human skeletal muscles tissues. To prepare the
total lysate, tissues were lysed in 20 mM Tris-HCl buffer
(pH 7.4) containing 10mM Na4P2O7, 100mM NaF, 2 mM
Na3VO4, 1% NP-40, and a protease inhibitor cocktail
(10 µg/µl aprotinin, 10 µg/µl leupeptin and 1mM PMSF).
The lysates were sonicated two times for 15 s each, and
the cell debris was removed by centrifugation (13,000
rpm) for 30min at 4 °C. To prepare crude mitochondria,
the tissues were homogenized in mitochondria isolation
buffer (250 mM sucrose, 25 mM Tris-HCl pH 7.4, 1 mM
EDTA) at 4 °C. Subsequently, the lysates were centrifuged
at 1000 × g to separate the nuclear and cytosolic fraction,
and the cytosolic fraction was further centrifuged at
10,000 × g at 4 °C to obtain a crude mitochondria pellet.
The pellet was dissolved in protein lysis buffer. Approxi-
mately 20–30 µg of the total lysate and crude mitochon-
drial fractions were separated by SDS-PAGE. Separated
proteins were transferred onto the nitrocellulose mem-
brane (Whatman, Dassel, Germany). The membrane was
blocked with 5% skim milk in Tris-buffered saline-
Tween20 (TBS-T) for 1–2 h at room temperature and
then was probed overnight at 4 °C with speciﬁc antibodies
against the selected mitochondrial proteins (Supplemen-
tary Table S2).
Results
Comprehensive proﬁling of the mitochondrial proteome
To investigate mitochondrial proteomes associated with
T2DM, we ﬁrst selected nine T2DM patients (n= 9;
four males and ﬁve females) and nine nondiabetic con-
trols (n= 9; ﬁve males and four females). The character-
istics of the T2DM patients and nondiabetic controls,
such as age, gender, body mass index, fasting blood
glucose, and other laboratory measures, are summarized
in Supplementary Table S1. From each of the T2DM
patients and normal controls, we obtained skeletal muscle
tissues and then isolated mitochondria using a previously
described method16 (see Materials and methods). To
facilitate detection of membranous proteins that are
closely associated with mitochondrial physiology, we used
the FASP13,40 method for protein digestion (see Materials
and methods). We then performed triplicate LC-MS/MS
experiments on each of the resulting peptide samples
from nine T2DM patients and nine nondiabetic controls,
resulting in 54 (18 × 3) LC-MS/MS datasets (Fig. 1a,
left branch; Supplementary Figures S2 and S3). In addi-
tion to skeletal muscle mitochondria, we further isolated
mitochondria from wild-type cybrid cells as previously
reported15, used the FASP method for protein digestion,
carried out offgel fractionation of the resulting peptide
samples into 26 fractions, and then performed LC-MS/
MS experiments for the fractions, resulting in 26 LC-MS/
MS datasets (Fig. 1a, right branch; Supplementary
Figure S4).
Next, we constructed a master AMT DB for the mito-
chondrial proteome using the total 80 LC-MS/MS
datasets from skeletal muscle (54 datasets) and cybrid
mitochondria (26 datasets) as previously described41. To
achieve this goal, we generated UMCs of peptide MS
features using iPE-MMR analysis22, assigned peptide
IDs and NETs to the UMCs (identiﬁed UMCs), which
were obtained from the target-decoy MS-GF+ search
(FDR < 0.01) and NET calculation, respectively, and then
complied all the identiﬁed UMCs from the 80 datasets
into an AMT DB (Fig. 1a, bottom; see Materials and
methods; Supplementary Figure S1). This procedure
resulted in the master AMT DB comprising 42,132 pep-
tides (or AMTs) (Fig. 1b, dots). For each dataset (Fig. 1c,
top), we then used the master AMT DB to assign peptide
IDs to unidentiﬁed UMCs (red dots in Fig. 1c, bottom)
with a mass tolerance of 10 ppm and NET tolerance of
0.025. As a result, 23,122 peptides were identiﬁed from
54 LC-MS/MS datasets that were generated from nine
T2DM and nine control skeletal muscle samples. Among
them, we then selected 7635 peptides that were detected
in more than half of the T2DM (n ≥ 5) and control (n ≥ 5)
samples to focus on the peptides with statistical power in
the comparison of their abundances between the T2DM
and control (Supplementary Figure S5). These 7635
peptides were mapped to 1671 proteins. Of them, as
mitochondrial proteins with high conﬁdence, we ﬁnally
selected 1171 proteins (1150 protein-coding genes) with
two or more sibling peptides (Supplementary Table 2).
Characteristics of mitochondrial proteome from skeletal
muscle
To assess the comprehensiveness of our mitochondrial
proteome from skeletal muscle tissues, we compared our
Chae et al. Experimental & Molecular Medicine (2018) 50:129 Page 6 of 14
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1150 proteins with the most comprehensive mouse and
human mitochondrial proteomes reported in two pre-
vious studies42,43. Paglianini et al.42 provided a mito-
chondrial compendium of 1098 protein-coding genes
from an integrated analysis of (1) LC-MS/MS proﬁles of
mitochondria isolated from 14 mouse tissues, (2) mito-
chondrial proteins reported in previous literature, and
(3) GFP tagging microscopy data. The 1098 genes were
mapped to 1012 human orthologs based on the human-
mouse ortholog information in the Mouse Genome
Informatics database. Lefort et al.43 proﬁled the proteome
of mitochondria isolated from human skeletal muscles
and then identiﬁed 823 proteins, which were mapped to
803 protein-coding genes. The comparison showed that
our 1150 mitochondrial protein-coding genes included
397 (39.2% of 1012) and 481 (60.0% of 803) protein-
coding genes (in total 558) identiﬁed from 14 mouse tis-
sues and human skeletal muscle tissues, respectively
(Fig. 2a). The remaining 592 of 1150 protein-coding genes
were not reported in the two previous mitochondrial
proteomes. These data suggest that our proteome from
skeletal muscle tissues can serve as a comprehensive
source of human tissue mitochondrial proteomes.
To understand the characteristics of our mitochondrial
proteome, we then examined the cellular localization of
the 1150 proteins based on the Gene Ontology Cellular
Components (GOCCs)44. The largest number of proteins
(455 of 1150; 39.6%) was found to be localized in mito-
chondria, followed by plasma membrane and cytosol/
cytoskeleton (Fig. 2b; Supplementary Table S3A). Com-
parison of mitochondrial proteomes detected by LC-MS/
MS showed that the fraction (39.6%) of proteins
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Fig. 2 Comprehensive proﬁles of the mitochondrial proteome. a Comparison of our proteome with two previous mitochondrial proteomes. For
the proteins detected in individual studies, the numbers of genes encoding the proteins are shown. Venn diagram showing the relationships of our
mitochondrial proteome with the largest previous mitochondrial proteomes. b Relative proportions of cellular components (GOCCs) in which the
measured mitochondrial proteins are mainly localized. In each stacked bar, the red bar represents the proportion of proteins that can be localized to
mitochondria according to GOCCs (e.g., 40 of 228 plasma membranous proteins can be co-localized to mitochondria). c Distribution of the
mitochondrial proteins in sub-mitochondrial localization. d Cellular processes (GOBPs) in which the identiﬁed proteins are mainly involved. The bars
represent–log10(P), where P represents the signiﬁcance of each GOBP enriched by the mitochondrial proteins. The P-value was computed using
DAVID software. e, f Coverage of the mitochondrial proteome in oxidative phosphorylation complexes. In the stacked bars, the purple bars represent
the proportions of proteins detected for all of the proteins included in complex I-V (e) and encoded by the nucleus (Nu-DNA) or mitochondria
genome (MT-DNA) (f)
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annotated with mitochondrion based on GOCCs was
comparable to those reported in Paglianini et al.42 and
Lefort et al.43 mentioned above (see 'Discussion'). More-
over, the localization distribution of the mitochondrial
455 proteins in our study further revealed that our
proteome included the proteins localized in the whole
spectrum of sub-mitochondrial compartments, ranging
from the mitochondrial outer and inner membranes to
the inner membrane space and mitochondrial matrix
(Fig. 2c). Next, we examined the cellular processes
represented by the 1150 proteins by performing enrich-
ment analysis of Gene Ontology Biological Processes
(GOBPs) using DAVID software34. The cellular processes
signiﬁcantly (P < 0.05) represented by the mitochondrial
proteome included processes related to T2DM-associated
mitochondrial functions in skeletal muscles, such as
oxidative phosphorylation (OXPHOS), glycolysis, the tri-
carboxylic acid (TCA) cycle, mitochondrion organization/
transport, fatty acid beta-oxidation, response to oxidative
stress, and translation (Fig. 2d; Supplementary Table S3B).
For the OXPHOS complexes, our proteome provided
comprehensive coverage (48–100%) of the proteomes
in all ﬁve complexes (Fig. 2e), regardless of the
mitochondria-encoded or nuclear-encoded OXPHOS
proteins (Fig. 2f). These data suggest that in addition
to the comprehensiveness, our mitochondrial proteome
provided a wide range of the mitochondrial proteome
involved in various pathophysiological processes that
occur in sub-mitochondrial compartments.
The mitochondrial proteome of skeletal muscle that is
altered in T2DM
In skeletal muscles, T2DM has been associated with
mitochondrial dysfunction involving alterations in the
abundance of mitochondrial proteomes45–47. To identify
the mitochondrial proteins with altered abundances in
T2DM, in comparison to nondiabetic controls, we ﬁrst
aligned the peptides measured in the 54 LC-MS/MS
datasets (27 for nine T2DM patients and 27 for nine
nondiabetic controls) and then identiﬁed 523 differen-
tially expressed peptides between T2DM and nondiabetic
controls using a previously reported method28 (see
Materials and methods). The 523 peptides were mapped
into 335 DEPs between T2DM and nondiabetic controls.
Among the 335 DEPs, 135 proteins were upregulated in
T2DM compared with the nondiabetic controls, whereas
200 proteins were downregulated (Fig. 3a; Supplementary
Table S4). To understand the functional association of
the DEPs with T2DM, we identiﬁed cellular processes
represented by the upregulated and downregulated pro-
teins using DAVID software (see Materials and methods).
This analysis revealed that the 135 upregulated proteins
were mainly involved in processes related to molecular
transport (calcium ion transport, protein transport, and
calcium ion homeostasis) and cytoskeletal organization
(muscle contraction, actin ﬁlament-based process, and
actin cytoskeleton organization) (Fig. 3b; Supplementary
Table S5A), consistent with previous ﬁndings that
molecular transport and cytoskeletal organization have
been linked to T2DM pathogenesis47. By contrast, the
200 downregulated proteins were mainly involved in
metabolic processes, such as glucose (glycolysis) and
fatty acid metabolic processes (fatty acid beta-oxidation)
and the TCA cycle, which can greatly contribute to
T2DM pathogenesis (Fig. 3c; Supplementary Table S5B).
Interestingly, however, both the upregulated and down-
regulated proteins (6 and 16 proteins, respectively)
signiﬁcantly represented OXPHOS. The conﬂicting
alteration patterns of OXPHOS proteins were consistent
with those found for OXPHOS genes in previous
studies45.
To explore the collective function of the aforemen-
tioned T2DM-associated processes, we reconstructed
network models (Fig. 3d, e) describing interactions among
the DEPs involved in the GOBPs related to molecular
transport, metabolism, and cytoskeletal organization
(see Materials and methods). First, the network model in
Fig. 3d showed a downregulation of metabolic pathways,
including the glycolytic pathway (HK1, GPI, PGM1,
ENO3, and PKM), TCA cycle (ACO2, IDH3A, OGDH,
DLST, SUCLA2, SDHA, FH, and MDH1), and fatty acid
β-oxidation (ACADM, DECR1, ECH1, HADH, and
HADHB) in T2DM compared with the nondiabetic
controls. Consistent with the downregulation of these
pathways, the network model further showed that
the transport of glucose and aspartate (SLC25A12), pyr-
uvate (MCP1/2), malate and α-ketoglutarate (SLC25A11),
and fatty acids (ACSL1 and CPT1B/2) were also down-
regulated in T2DM. Additionally, the proteins in the ﬁve
OXPHOS complexes were largely downregulated in
T2DM, while conversely, several proteins (ATP5O and
NDUFA6/A7/A12/AB1/S6) were upregulated, suggesting
complex alteration patterns of the OXPHOS system in
T2DM. Moreover, mitochondrial protein transport
(TIMM44) was downregulated in T2DM, together with
molecular chaperones (HSPA1A/D1). Furthermore, the
network model also revealed a downregulation of calcium
(MICU1 and VDAC1/3) and ATP transport (SLC25A4
and VDAC1/3). Collectively, the downregulation of these
key mitochondrial metabolic processes in the network
model suggests a decreased overall activity of mitochon-
drial metabolism in T2DM compared with nondiabetic
controls.
By contrast, the network model in Fig. 3e showed an
upregulation of several processes that were originally
reported to be associated with endoplasmic reticulum
(ER): ER calcium trafﬁcking (RYR1 and ATP2A1/A3)
(Fig. 3e, top), ER unfolded protein response (PDIA3/4 and
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ERP29), and vesicle-mediated protein trafﬁcking (SORT1,
RAB1A/10, STX7, and COPB1) (Fig. 3e, middle). These
ER cellular processes represented by the upregulated
mitochondrial proteins in T2DM suggest a potential
association of ER with mitochondrial functions in T2DM.
Recently, it has been reported that a subset of mito-
chondria are in close contact with the ER, forming the
interface called the mitochondria-associated ER mem-
brane (MAM)48–50, and the functions of the MAM are
increased when mitochondrial functions are decreased
under pathological conditions51. Interestingly, among
MAM proteins that have been previously reported in
several studies, a signiﬁcant (40.1%; 15 of 37 previous
MAM proteins) portion of them were detected in our
mitochondrial proteome (Supplementary Table S6).
These data suggest that our mitochondrial samples that
included MAMs and upregulated MAM proteins (Fig. 3e)
can also be used to establish a mitochondrial proﬁle that
is indicative of T2DM-associated mitochondrial functions
(see 'Discussion'). Finally, the network model (Fig. 3e,
bottom) showed upregulation of a cytoskeletal organiza-
tion pathway (ITGB1, RHOA, MYLPF, DOCK2, PDLIM3,
a b c
d e
Fig. 3 Network models delineating cellular processes represented by T2D-associated mitochondrial proteins (DEPs). a Heat maps showing
differential expression of 523 peptides with altered abundances between T2DM patients and nondiabetic controls. Colors represent upregulation
(red) and downregulation (green) in T2DM compared with nondiabetic controls. The color bar denotes the gradient of the auto-scaled intensities
with a mean= 0 and standard deviation= 1. b, c Cellular processes (GOBPs) represented by upregulated (b) and downregulated (c) proteins. The
bars represent –log10(P), where P represents the signiﬁcance of each GOBP enriched by the DEPs. d, e Network models describing the interactions of
the DEPs in mitochondria (d) and MAM (e) and their ﬁrst neighbors involved in the selected GOBPs. The node colors represent upregulation (red) and
downregulation (green) in T2DM compared with nondiabetic controls. The color bar denotes the gradient of the log2-fold changes between T2DM
and nondiabetic controls. The edges represent protein–protein interactions (gray) collected from four interactome databases
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ACTN4, DES, DYNC1H1, and TPM1) in T2DM com-
pared with nondiabetic controls, while conversely, several
molecules (FLNA, ACTA1/C1, ACTN2, and TNNC1) in
the pathway were downregulated.
A mitochondrial proteome proﬁle indicative of T2DM
pathophysiology
The above-described network models revealed the
following representative T2DM-associated cellular path-
ways: mitochondrial metabolic pathways (Fig. 3d) and
MAM-associated cellular pathways for ER calcium traf-
ﬁcking (Fig. 3e, top) and ER unfolded protein response
and transport (Fig. 3e, middle). Thus, we selected a
mitochondrial proteome proﬁle indicative of T2DM
pathophysiology as representative proteins of these
three T2DM-associated cellular processes (Supplemen-
tary Figure S6). First, in skeletal muscles of human sub-
jects and rodents with T2DM, mitochondrial metabolic
dysregulation, involving impairment of OXPHOS, has
been observed in insulin-resistant states2,52,53, consistent
with the downregulated OXPHOS in the network model
(Fig. 3d). As a mitochondrial proteome proﬁle indicative
of T2DM-associated mitochondrial functions, we thus
selected the two representative proteins for the down-
regulated OXPHOS (Supplementary Figure S6): (1–2)
downregulated NDUFS3 (Complex I) and COX2 (Com-
plex IV). Second, mitochondrial dysfunction has been
shown to be linked to impaired calcium transport54–56,
which can subsequently alter calcium homeostasis in
the MAM57, consistent with the upregulated calcium
transport at the MAM in the network model (Fig. 3e, top).
Third, mitochondrial dysfunction has also been reported
to result in decreased protein transport into mitochon-
dria58, which can then alter protein transport in the
MAM, consistent with the upregulated protein transport
at the MAM in the network model (Fig. 3e, middle). Thus,
we selected the following three representative proteins
for calcium and protein transports as an additional
mitochondrial proteome proﬁle indicative of T2DM-
associated mitochondrial functions (Supplementary Fig-
ure S6): (3) upregulated CALR for calcium transport and
(4–5) upregulated SORT1 and RAB1A for protein
transport.
Validation of the selected mitochondrial protein proﬁle
indicative of T2DM
To experimentally test the validity of the ﬁve selected
proteins, we ﬁrst conﬁrmed the differential expression of
the ﬁve selected proteins in diabetic mouse high fat diet
(HFD)-induced obesity models using western blot analysis
(see Materials and methods). We have previously shown
that body weight, fat mass, blood glucose levels, and blood
insulin levels in HFD-fed (6 weeks) mice are signiﬁcantly
higher than those in normal chow diet-fed mice59.
Consistent with the LC-MS/MS data, SORT1, CALR, and
RAB1A were signiﬁcantly (P < 0.05) upregulated in both
skeletal muscle tissues of HFD-fed mice (Fig. 4a; Sup-
plementary Figure S7a) and mitochondria isolated from
the skeletal muscle tissues (Fig. 4b; Supplementary Fig-
ure S7b) compared with the corresponding samples from
normal chow diet-fed mice. We also conﬁrmed that
COXII and NDUFS3 were signiﬁcantly (P < 0.05) down-
regulated in both skeletal muscles (Fig. 4a; Supplementary
Figure S8a) and mitochondria from skeletal muscles of
HFD-fed mice (Fig. 4b; Supplementary Figure S8b), con-
sistent with the LC-MS/MS data. Moreover, to conﬁrm
the differential expression of the ﬁve selected proteins in
human skeletal muscle tissues, we further collected ske-
letal muscle tissues from an independent set of 14 T2DM
patients and 12 nondiabetic controls based on the same
criteria employed for the collection of samples during the
discovery phase using LC-MS/MS analysis (Supplemen-
tary Table S1; see Materials and methods). Consistent
with LC-MS/MS data, SORT1, CALR, and RAB1A
showed signiﬁcantly (P < 0.05) upregulation patterns in
both skeletal muscle tissues of T2DM patients (Fig. 4c)
and mitochondria isolated from them (Fig. 4d) compared
with the nondiabetic controls. Similarly, COX2 and
NDUFS3 showed signiﬁcantly (P < 0.05) downregulation
patterns in both skeletal muscle tissues of T2DM patients
(Fig. 4c) and their mitochondria (Fig. 4d) compared with
the nondiabetic controls. Taken together, these results
suggest that the selected mitochondrial proteome proﬁle
can serve as an indicator of T2DM-associated dysregula-
tion of mitochondrial functions, upregulated MAM
functions and downregulated OXPHOS.
Discussion
In skeletal muscles, mitochondrial functions are essen-
tial in the pathogenesis of T2DM. Thus, a mitochondrial
proteome proﬁle indicative of mitochondrial functions
can serve as a key dimension of molecular signatures to
understand the pathogenesis of T2DM. Despite its
potential importance, the mitochondrial proteome proﬁle
has not been systematically explored. In this study, we
thus examined the comprehensive proteome proﬁle of
mitochondria isolated from skeletal muscles in T2DM
patients to identify a proﬁle representing key mitochon-
drial functions associated with the pathogenesis of T2DM.
To achieve this goal, we developed an approach that
involves (1) comprehensive label-free proteome proﬁling
of mitochondria after the isolation of mitochondria from
skeletal muscles, followed by FASP digestion and ultra-
high pressure nano-LC-MS/MS analysis; (2) generation of
a master AMT DB by performing offgel-based extensive
fractionation; (3) identiﬁcation of mitochondrial DEPs
between T2DM and nondiabetic controls; (4) selection of
a protein proﬁle that can represent T2DM-associated
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mitochondrial functions based on functional and network
analyses of the DEPs; and (5) validation of the selected
protein proﬁle in independent human and mouse T2DM
samples using western blotting. Using this approach, we
identiﬁed a protein proﬁle composed of ﬁve mitochon-
drial proteins (three upregulated SORT1, CALR, and
RAB1A representing calcium and protein transports, and
two downregulated COX2 and NDUS3 representing
OXPHOS).
In our mitochondrial proteome, the fraction of proteins
annotated with mitochondrion, according to GOCC, was
found to be 39.6% (455 of 1150 proteins; Supplementary
Table 4). This fraction might be considered to be too low,
thus casting doubt on our experimental protocol for the
isolation of mitochondria from skeletal muscle tissues.
To examine this issue, we compared the fraction in our
study with those in the two previous studies. Paglianini
et al.42 detected 3881 potential mitochondrial proteins
by LC-MS/MS analyses of pure and crude fractions of
mitochondria and then selected 2859 of 3881 mitochon-
drial proteins by removing 1022 that were relatively
enriched in crude fractions of mitochondria, compared
with the pure fractions. The 2859 proteins were mapped
to 2464 protein-coding genes. Of the 2464 genes, 629
(25.6%) were found to be localized in mitochondria based
on GOCCs. Furthermore, Lefort et al.43 identiﬁed 823
mitochondrial proteins that were mapped to 803 protein-
coding genes. Of the 803 genes, 405 (50.4%) were found
to be localized in mitochondria based on GOCCs. Thus,
the average of the fractions in the two previous studies
is 38.0%, which is close to the fraction (39.6%) in our
study. In addition to GOCCs, the protein atlas database
provides protein subcellular localization data obtained via
immunoﬂuorescence (IF) staining analysis60. According
to these data, of our 1150 mitochondrial proteins, 277
(24.1%) were localized in mitochondria (Supplementary
Table 4), and 503 (20.4%) of 2464 proteins and 316
(39.4%) of 803 proteins in the two previous studies were
localized in mitochondria. As in the case of GOCCs, the
fraction (24.1%) in our data was close to the average
fraction (29.9%) in the two previous studies. These data
suggest that our experimental protocol used for the iso-
lation of mitochondria was as effective as those in the
previous studies for identifying mitochondrial proteins
using LC-MS/MS analysis.
Interestingly, large portions of 1150 detected proteins
and 335 DEPs not annotated with mitochondria, based
on the IF or GOCC data, were found to be localized in
MAMs, according to the two MAM proteomes previously
reported (Supplementary Tables 4 and 6)61,62. Among the
1150 detected proteins, 682 were not annotated with
mitochondria according to the IF or GOCC data, and
420 (61.6%) were found to be localized to the MAMs
(Supplementary Figure S9a). Furthermore, among the
Fig. 4 Validation of the selected proteins in independent samples. a-d Protein expression levels of the ﬁve selected proteins (SORT1, CARL,
RAB1A, COX2, and NDUFS3) in T2DM and nondiabetic samples. SORT1, CARL, and RAB1A were upregulated in high fat diet-fed mice (diabetic
conditions) compared with normal chow diet-fed mice (nondiabetic conditions), whereas COX2 and NDUFS3 were downregulated. Total proteins
(a; WCL) and mitochondria fractions (b; Mito) were prepared from skeletal muscle tissues of normal chow diet- and high fat diet-fed mice (n= 11).
Furthermore, total proteins (c; WCL) and mitochondria fractions (d; Mito) were prepared from human skeletal muscle tissues of T2DM patients
(n= 14) and nondiabetic controls (n= 12). The data are shown as the mean ± SEM. *P < 0.05, **P < 0.01 by the Mann–Whitney test
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335 DEPs, 184 were not annotated with mitochondria,
and 109 (59.2%) were localized to the MAMs (Supple-
mentary Figure S9b). Moreover, these 109 MAM-
localized DEPs showed systematic differential expression
between T2DM and NGT mitochondrial samples. These
data suggest that the MAM-localized proteins, in addition
to mitochondria-localized DEPs, may serve as indicators
of T2DM-associated functions of mitochondria or
MAMs. Thus, we included these MAM-localized DEPs
when selecting the representative biomarker candidates.
Among the ﬁve selected candidates, NDUFS3 and COX2
involved in OXPHOS were mitochondria-localized DEPs,
while CALR, SORT, and RAB1A involved in calcium and
protein transport were MAM-localized DEPs, consistent
with the ﬁndings in the network models (Fig. 3d, e).
Previous studies have shown associations of the ﬁve
proteins selected in this study with T2DM in insulin-
secreting or responsive tissues/cells (pancreatic β cells,
skeletal muscles, adipocytes, or liver tissues): (1) the
amounts of SORT1 in liver and adipose tissues were
associated with obesity, insulin resistance, and T2DM63,64,
and SORT1 was found to be an essential component for
the formation of GLUT4 storage vesicles in adipocytes
and for the insulin-responsiveness of GLUT4 transloca-
tion to the plasma membrane;65 (2) the protein levels of
CALR were elevated in adipose tissues of obese indivi-
duals compared with controls66, and the CALR gene
mutation was associated with the risk of T2DM;67 (3)
RAB1A was reported to mediate proinsulin-to-insulin
conversion, and the abundance of RAB1A was decreased
in pancreatic β cells of T2DM patients compared with
nondiabetic controls;68 (4) the mRNA level of NDUFS3
was downregulated in skeletal muscles of T2DM patients
compared with nondiabetic controls;69,70 (5) the protein
level of COX was downregulated in pancreatic β cells
of T2DM patients compared with nondiabetic controls
and linked to insulin resistance and β cell failure71.
However, mitochondrial associations of SORT1, CALR,
and RAB1A and T2DM-associated alterations of their
protein levels in the MAM or mitochondria have been
never reported in insulin-secreting or responsive tissues/
cells. These data indicate two aspects of the ﬁve protein
panel: (1) the alterations of protein levels of these proteins
in insulin-responsive tissues suggest a potential utility of
the ﬁve proteins as a protein proﬁle that can represent
T2DM-associated mitochondrial functions; and (2) no
associations of three upregulated proteins (SORT1,
CALR, and RAB1A) with mitochondria in T2DM
patients, as well as their alterations in protein levels, have
previously been shown.
Several proteomic studies have described mitochondrial
proteomes in various systems and/or lists of proteins
localized in mitochondria. Paglianini et al.42 and Lefort
et al.43 provided comprehensive mitochondrial proteomes
of 14 mouse tissues and skeletal muscles, respectively
(Fig. 2a). Although they could have served as useful
resources for various studies of mitochondrial physiology,
neither has compared their mitochondrial proteomes with
those in T2DM, thus providing no lists of DEPs in T2DM
compared with nondiabetic controls. Of the ﬁve selected
proteins, three (RAB1A, NDUFS3, and COX2) were
detected in one of these studies, but alterations of their
abundances in T2DM have remained unknown. Second,
several studies8,9,47,71 have performed comparative pro-
teomic analyses in muscle, salivary, serum, and pancreatic
islet tissues between T2DM and nondiabetic samples,
providing the lists of DEPs in T2DM compared with
nondiabetic controls. Of the ﬁve proteins, four (CALR,
RAB1A, NDUFS3, and COX2) were detected in one of
these tissues (Supplementary Table S7). Nonetheless,
none of the ﬁve selected proteins has been previously
reported to be altered in protein levels in mitochondria of
insulin-responsive tissues.
The network analysis suggested that our mitochondrial
proteome may include the proteins in MAMs (Fig. 3e,
top and middle). Most of these MAM proteins were
upregulated in T2DM compared with nondiabetic con-
trols, while the mitochondrial proteins shown in Fig. 3d
were largely downregulated in T2DM. These alterations
in both MAM and mitochondrial proteins suggest
their functional coordination in T2DM, as previously
demonstrated in Alzheimer’s disease51. By contrast, the
opposite alteration patterns (e.g., calcium and protein
transport in MAM and mitochondria) may reﬂect possible
compensatory responses for the decreased activity of the
mitochondrial processes by the MAM. Interestingly,
alterations of the three selected proteins (SORT1, CALR,
and/or RAB1A) for the MAM processes (Fig. 3e) were
reliably conﬁrmed in skeletal muscle and mitochondrial
samples from both the HFD-fed mouse model and inde-
pendent human cohorts (Fig. 4a–d). Collectively, these
data suggest that MAM proteins can serve as useful
indicators of T2DM-associated mitochondrial functions.
Taken together, our study showed the differential
expression of the ﬁve selected proteins, some of which
have previously been linked to T2DM pathogenesis in
other systems in mitochondria of skeletal muscle tissues
from T2DM patients, thereby supporting their potential
use as a protein proﬁle that is indicative of T2DM-
associated mitochondrial functions. The clinical implica-
tions of the selected proteins can be further tested with a
larger number of T2DM patients. In addition, longitudinal
studies can be designed to further demonstrate the nature
of the dynamic changes in the proposed protein proﬁle
during the course of T2DM progression. Although we
focused on the ﬁve proteins selected in this study, our
approach further provided 330 other mitochondrial DEPs
that may also be associated with mitochondrial functions
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in skeletal muscles of T2DM patients. For example, in
the network models, many of the proteins involved in
mitochondrial metabolic pathways (Fig. 3d) and cellular
pathways in the MAM (Fig. 3e), like the ﬁve selected
proteins, have been reported to be associated with T2DM-
associated alterations (Supplementary Table 8). These
proteins can also be used as additional indicators of
T2DM-associated mitochondrial functions together with
the ﬁve selected proteins. Thus, these proteins extensively
extend the current list of T2DM-associated mitochondrial
proteins identiﬁed using conventional small-scale
experiments or approaches. This list of proteins can
serve as a comprehensive resource for the study of func-
tional links of mitochondrial functions to the pathogen-
esis of T2DM. Furthermore, the network models further
suggest functional links of calcium and protein transport
in the MAM to mitochondrial dysregulation in T2DM
skeletal muscles. This understanding further suggests a
potential therapeutic option involving the modulation
of mitochondrial functions during the pathogenesis of
T2DM. In summary, our approach effectively identiﬁed
a protein proﬁle that can provide a novel dimension of
information indicative of T2DM-associated mitochondrial
functions.
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